Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Accured Expenses (2016 - 2025)

Vanda Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 526.75% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $15.8 million, up 826.23%, while the annual FY2025 figure was $15.8 million, 826.23% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $9.1 million at Vanda Pharmaceuticals, up from -$10.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $13.4 million in Q1 2022 and bottomed at -$10.8 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $735500.0 (2022), against an average of $1.1 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 4878.57% in 2022 before it plummeted 2079.74% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2021, then tumbled by 250.32% to -$3.3 million in 2022, then surged by 201.65% to $3.3 million in 2023, then plummeted by 163.85% to -$2.1 million in 2024, then skyrocketed by 526.75% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Change in Accured Expenses are $9.1 million (Q4 2025), -$10.2 million (Q3 2025), and $11.3 million (Q2 2025).